PAK1 and cardiac arrhythmia: And fingolimod [PAK1 activator, an Food and Drug Administration (FDA)-approved drug] was proved to prevent arrhythmias and cardiac hypertrophy (Yun et al., 2016; Chen et al., 2018; Supplementary Figure 3B).